SCINAI IMM.ADS/4000 IL-01 (2F5.F)

2.6200 -0.3000 (-10.27%) At close: 03:29PM CEST

SCINAI IMM.ADS/4000 IL-01

Jerusalem BioPark
2nd floor Hadassah Ein Kerem Campus
Jerusalem
Israel
972 8 930 2529
https://www.scinai.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 31

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Amir Reichman M.B.A., M.Sc.	CEO & Director	524.84k	N/A	1976
Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA	Chief Financial Officer	159.69k	N/A	1970
Mr. Elad Mark B.Sc., Eng., M.B.A.	Chief Operating Officer	219.46k	N/A	1983
Dr. Dalit Weinstein Fischer Ph.D.	Chief Technology Officer	199.85k	N/A	1971
Dr. Tamar Ben-Yedidia Ph.D.	Chief Scientist	237.2k	N/A	1964
Mr. Joshua E. Phillipson B.Sc., M.B.A.	Director of Communications & Investor Relations	N/A	N/A	N/A
Liat Halpert	Head of Business Development & Sales	N/A	N/A	N/A
Merav Kamensky	Head of Quality Control	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Corporate governance

SCINAI IMM.ADS/4000 IL-01’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.